proteasome inhibitors (QLi5 Therapeutics)

N/A

Report date: 2025/06/11 10:24:26
NME

Base Information

Drug Nameproteasome inhibitors (QLi5 Therapeutics)
Drug Alias Nameproteasome inhibitors (Lead Discovery)LDC-6256QL-1001LDC-1135LDC-6783 +[6] 
ClassificationSmall molecules
Mechanisms of ActionProteasome inhibitors
TargetsProteasome
Therapy Area/IndicationsSolid tumoursInflammationSkin Diseases +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLead Discovery Center GmbH
China Registration ClassN/A

Develop Information

Active CompaniesQLi5 Therapeutics GmbH
Inactive CompaniesLead Discovery Center GmbH
Active IndicationsSolid tumoursInflammationMultiple Myeloma
Inactive IndicationsSkin DiseasesAsthmaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A